|
業務類別
|
Biotechnology |
|
業務概覽
|
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders. |
| 公司地址
| One World Trade Center, 29th Floor, New York, NY, USA, 10007 |
| 電話號碼
| +1 212 332-3241 |
| 傳真號碼
| +1 212 320-0245 |
| 公司網頁
| https://www.axsome.com |
| 員工數量
| 925 |
| Dr. Herriot Tabuteau, M.D. |
Chairman of the Board, President and Chief Executive Officer |
美元 780.00K |
23/02/2026 |
| Mr. Mark Jacobson, M.A. |
Chief Operating Officer |
美元 552.00K |
25/04/2025 |
| Mr. Nick Pizzie |
Chief Financial Officer and Principal Accounting Officer |
美元 505.00K |
23/02/2026 |
| Mr. Hunter Murdock |
General Counsel |
美元 505.00K |
25/04/2025 |
| Mr. Ari Maizel |
Chief Commercial Officer |
美元 510.00K |
25/04/2025 |
|
|
| Mr. Mark E. Saad |
Independent Director |
23/02/2026 |
| Dr. Roger A. Jeffs, PhD |
Independent Director |
23/02/2026 |
| Dr. Susan Mahony, M.B.A.,PhD |
Independent Director |
23/02/2026 |
| Dr. Herriot Tabuteau, M.D. |
Chairman of the Board, President and Chief Executive Officer |
23/02/2026 |
| Dr. Mark Coleman, M.D. |
Independent Director |
23/02/2026 |
|
|
|
|
